• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

    29.69 +0.28 (+0.94%)
    Streaming Delayed Price Updated: 1:12 PM EDT, Aug 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 496,045
    Open 29.18
    Bid (Size) 29.68 (300)
    Ask (Size) 29.69 (100)
    Prev. Close 29.41
    Today's Range 28.83 - 29.85
    52wk Range 19.69 - 29.76
    Shares Outstanding 162,625,379
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript ↗
    Revenue hit $308 million with 17% growth, driven by DAYBUE and NUPLAZID demand. 
    Via The Motley Fool
    Topics Earnings
    ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 Earnings Beat, Stock Rises on Raised Guidance ↗
    Via Chartmill
    Topics Earnings

    Performance

    YTD
    +12.9%
    +12.9%
    1 Month
    +16.4%
    +16.4%
    3 Month
    +36.7%
    +36.7%
    6 Month
    +30.8%
    +30.8%
    1 Year
    +19.5%
    +19.5%

    More News

    Read More
    News headline image
    ACADIA Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Why Acadia Pharmaceuticals Stock Is Soaring Today ↗
    Via The Motley Fool
    Traders are paying attention to the gapping stocks in Friday's session. ↗
    Via Chartmill
    News headline image
    Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday ↗
    Via Benzinga
    News headline image
    DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth ↗
    Via MarketBeat
    News headline image
    ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms ↗
    Via MarketBeat
    News headline image
    Acadia (ACAD) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
    Via MarketMinute
    News headline image
    Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire

    Frequently Asked Questions

    Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
    Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
    What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
    ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
    The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
    What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
    The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 29.69
    When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
    The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 08/12/26 01:12 PM ET
    What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
    The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 4.83B
    How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
    ACADIA Pharmaceuticals Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.